Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Videos|November 5, 2021
Addressing the Established Understanding of How the Use of Aspirin Impacts the Treatment of Chronic Kidney Disease
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the established understanding of how the use of aspirin impacts the treatment of chronic kidney disease.
Advertisement
Pharmacy Times interviewed Jun Ling Lu, MD, assistant professor, Department of Medicine, University of Tennessee Health Science Center, on her presentation at the American Society of Nephrology’s Kidney Week 2021 on the association between long-term aspirin use and the progression of kidney disease.
During the discussion, Lu addressed the established understanding of how the use of aspirin impacts the treatment of chronic kidney disease prior to the results of her research.
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
3
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
4
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
5